References
1.
Berndt MC, Andrews RK: Bernard-Soulier syndrome. Haematologica 2011;96:355-359.
2.
Kunishima S, Kamiya T, Saito H: Genetic abnormalities of Bernard-Soulier syndrome. Int J Hematol 2002;76:319-327.
3.
Lanza F: Bernard-Soulier syndrome (hemorrhagiparous thrombocytic dystrophy). Orphanet J Rare Dis 2006;1:46.
4.
Savoia A, Pastore A, De Rocco D, Civaschi E, Di Stazio M, Bottega R, Melazzini F, Bozzi V, Pecci A, Magrin S, Balduini CL, Noris P: Clinical and genetic aspects of Bernard-Soulier syndrome: searching for genotype/phenotype correlations. Haematologica 2011;96:417-423.
5.
Kunishima S, Saito H: Advances in the understanding of MYH9 disorders. Curr Opin Hematol 2010;17:405-410.
6.
Kunishima S, Lopez JA, Kobayashi S, Imai N, Kamiya T, Saito H, Naoe T: Missense mutations of the glycoprotein (GP) Ibβ gene impairing the GPIb α/β disulfide linkage in a family with giant platelet disorder. Blood 1997;89:2404-2412.
7.
Kunishima S, Hayashi K, Kobayashi S, Naoe T, Ohno R: New enzyme linked immunosorbent assay for glycocalicin in plasma. Clin Chem 1991;37:169-172.
8.
Kurokawa Y, Ishida F, Kamijo T, Kunishima S, Kenny D, Kitano K, Koike K: A missense mutation (Tyr88 to Cys) in the platelet membrane glycoprotein Ibβ gene affects GPIb/IX complex expression. Thromb Haemost 2001;86:1249-1256.
9.
Zieger B, Jenny A, Tsakiris DA, Bartsch I, Sandrock K, Schubart C, Schäfer S, Busse A, Wuillemin WA: A large Swiss family with Bernard-Soulier syndrome - correlation phenotype and genotype. Hamostaseologie 2009;29:161-167.
10.
Vettore S, Scandellari R, Scapin M, Lombardi AM, Duner E, Randi ML, Fabris F: A case of Bernard-Soulier Syndrome due to a homozygous four bases deletion (TGAG) of GPIbα gene: lack of GPIbα but absence of bleeding. Platelets 2008;19:388-391.
11.
Kunishima S, Naoe T, Kamiya T, Saito H: Novel heterozygous missense mutation in the platelet glycoprotein Ibβ gene associated with isolated giant platelet disorder. Am J Hematol 2001;68:249-255.
12.
Balduini CL, Savoia A: Inherited thrombocytopenias: molecular mechanisms. Semin Thromb Hemost 2004;30:513-523.
13.
Kunishima S, Saito H: Congenital macrothrombocytopenias. Blood Rev 2006;20:111-121.
14.
Budarf ML, Konkle BA, Ludlow LB, Michaud D, Li M, Yamashiro DJ, McDonald-McGinn D, Zackai EH, Driscoll DA: Identification of a patient with Bernard-Soulier syndrome and a deletion in the DiGeorge/velo-cardio-facial chromosomal region in 22q11.2. Hum Mol Genet 1995;4:763-766.
15.
Hillmann A, Nurden A, Nurden P, Combrie R, Claeyssens S, Moran N, Kenny D: A novel hemizygous Bernard-Soulier syndrome (BSS) mutation in the amino terminal domain of glycoprotein (GP)Ibβ - platelet characterization and transfection studies. Thromb Haemost 2002;88:1026-1032.
16.
Ludlow LB, Schick BP, Budarf ML, Driscoll DA, Zackai EH, Cohen A, Konkle BA: Identification of a mutation in a GATA binding site of the platelet glycoprotein Ibβ promoter resulting in the Bernard-Soulier syndrome. J Biol Chem 1996;271:22076-22080.
17.
Tang J, Stern-Nezer S, Liu PC, Matyakhina L, Riordan M, Luban NL, Steinbach PJ, Kaler SG: Mutation in the leucine-rich repeat C-flanking region of platelet glycoprotein Ibβ impairs assembly of von Willebrand factor receptor. Thromb Haemost 2004;92:75-88.
2013
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or...
2013
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.